IXICO PLC (GB:IXI)
LSE:IXI
Want to see GB:IXI full AI Analyst Report?
IXI Stock Chart & Stats
11.75 p
-0.75 p(-6.25%)
At close: 4:00 PM EST
11.75 p
-0.75 p(-6.25%)
Day’s Range― - ―
52-Week Range6.26 p - 15.00 p
Previous CloseN/A
Volume22.18K
Average Volume (3M)123.87K
Market Cap
£18.53M
Enterprise Value4.55M
Total Cash (Recent Filing)£3.54M
Total Debt (Recent Filing)£179.00K
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Dec 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,047,590
10 Day Avg. Volume82,815
30 Day Avg. Volume123,868
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.50M
Bulls Say, Bears Say
Bulls Say
Order Book GrowthA materially larger order book and a 1.5 book-to-bill provide multi-month to multi-quarter revenue visibility, allowing management to plan capacity and SG&A. Durable backlog reduces near-term revenue volatility and underpins the company’s ability to scale toward profitable thresholds.
Specialized CNS & AI PlatformSpecialization in CNS trials combined with an AI-enabled biomarker analytics platform creates a high-value niche with technical barriers to entry. Long-term contracts, regulatory-grade outputs and domain expertise increase client stickiness and pricing power in pharma/biotech R&D.
Conservative Balance SheetA solid net asset base and cash buffer, together with low reported leverage, provide financial flexibility to invest in platform development and support operations during scaling. This reduces immediate refinancing risk and supports execution of multi-year commercialization plans.
Bears Say
Persistent EBITDA LossOngoing negative EBITDA indicates the business is not yet self-sustaining; even with loss reduction, persistent operating deficits constrain reinvestment and require external financing until scale economies are reached, making long-term margins and capital needs uncertain.
Weak Cash GenerationNegative operating cash flow and volatile free cash flow signal weak cash conversion from operations. This erodes runway, raises the likelihood of capital raises, and limits the firm's ability to fund platform R&D or support larger studies without dilutive financing.
Revenue Below BreakevenCurrent revenue sits well below management's stated breakeven threshold, requiring sustained high growth to reach profitability. Given historical revenue declines and margin pressure, failure to convert backlog into repeat high-margin contracts could delay or jeopardize achieving sustainable profits.
IXICO plc News
IXI FAQ
What was IXICO PLC’s price range in the past 12 months?
IXICO PLC lowest share price was 6.26 p and its highest was 15.00 p in the past 12 months.
What is IXICO PLC’s market cap?
IXICO PLC’s market cap is £18.53M.
When is IXICO PLC’s upcoming earnings report date?
IXICO PLC’s upcoming earnings report date is Dec 08, 2026 which is in 201 days.
How were IXICO PLC’s earnings last quarter?
IXICO PLC released its earnings results on May 19, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.
Is IXICO PLC overvalued?
According to Wall Street analysts IXICO PLC’s price is currently Overvalued.
Does IXICO PLC pay dividends?
IXICO PLC does not currently pay dividends.
What is IXICO PLC’s EPS estimate?
IXICO PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IXICO PLC have?
IXICO PLC has 218,047,590 shares outstanding.
What happened to IXICO PLC’s price movement after its last earnings report?
IXICO PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.778%.
Which hedge fund is a major shareholder of IXICO PLC?
Currently, no hedge funds are holding shares in GB:IXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IXICO PLC
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Physiomics
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---